|
Betacel is considered to be the first successfully commercialized betavoltaic battery.〔"Nuclear Battery," , Larry C. Olsen, Stephen E. Seeman, Bobby I. Griffin and Charles J. Ambrose.〕〔"The Betavoltaic Pacemaker Power Source," WE Matheson, Advances in Pacemaker Technology, M. Schaldach and S. Furman, Editors, Springer-Verlag, 1975, page 401, Proc. Int. Symp. on Advances in Pacemaker Technology Erlagen (1974). doi:(10.1007/978-3-642-66187-7_25 ).〕〔"Nuclear-Fueled Cardiac Pacemakers," Fred N. Huffman and John C. Norman, CHEST 65, page 667 - 672 (1974).〕 It was created with the use of Promethium-147 radioisotope as the beta-electron source and was coupled to silicon semiconductor cells. The betavoltaic program along with the development of the Betacel was led by Dr. Larry C. Olsen and a team of researchers at Donald W. Douglas Laboratories (DWDL), McDonnell Douglas Corporation, in the early 1970s.〔1970 - Tri-City Herald “Man of the Year”. Honor given by the Tri-City Herald of Tri-Cities, WA for leading the development of the Betacel nuclear battery at Donald W. Douglas Laboratories. See page 1 of the Tri-City Herald, January 1, 1971.〕 As the first (and only) viable betavoltaic power source ever developed, it was immediately used to power heart pacemakers. Betacel powered cardiac pacemakers were implanted in numerous patients in the 1970s. Biotronik GmbH & Co., Ingenieurburo, Berlin, adapted its chemical battery-powered pacemakers to accept the promethium-fueled Betacel battery. The Betacel powered Biotronik pacemakers were considered to have useful lives of 7 to 10 years.〔"Benefits and Risks of Promethium Battery-Powered Pacemakers," R. Franco and M.L. Smith, Advances in Pacemaker Technology, M. Schaldach and S. Furman, Editors, Springer-Verlag, 1975, page 539, Proc. Int. Symp. on Advances in Pacemaker Technology Erlagen (1974).〕 Clinical investigation of the Betacel-Biotronik pacemaker began in Europe in 1972 and was extended to the United States under State of Washington license in 1973. By early 1973, over 60 implanted Betacel- Biotronik pacemakers were being monitored as part of the clinical investigation.〔〔Benefit/Risk Analysis of Cardiac Pacemakers Powered by BETACEL Promethium-147 Batteries, T.H. Smith, J. Greenborg and W.E. Matheson, Nuclear Technology 26, May 1975.〕 By mid-1974, the USAEC had authorized the licensing in the United States of a Clinical Investigation Program that allowed the implantation of 50 Betacel-Biotronik pacemakers per month in major clinics in the U.S.〔"Benefits and Risks of Promethium Battery-Powered Pacemakers," R. Franco and M.L. Smith, Advances in Pacemaker Technology, M. Schaldach and S. Furman, Editors, Springer-Verlag, 1975, page 539, Proc. Int. Symp. on Advances in Pacemaker Technology Erlagen (1974).〕 During that same time period, there was a certain stigma associated with the use of nuclear power and radioactive materials; the public was genuinely fearful and leery of any nuclear technology. This stigma, combined with advances in (and the lower cost of) Lithium-Ion battery technology eventually overshadowed aspirations of a more lucrative future for the Betacel, relegating betavoltaic batteries to the realm of academic research in the years that immediately followed. The Betacel did not last but it provided a foundation for future betavoltaic technology research and sparked a resurgence of interest in betavoltaic power generation. Between 2001 and 2010, four commercial companies (City Labs, Inc., BetaBatt Inc., Qynergy, Inc. and Widetronix, Inc.) have ventured into betavoltaic power cell development, while university research on the subject is still actively being conducted. Rapid advances in semiconductor and materials science technology, integrated circuit design and fabrication, and micro- / nano-scale micro-electromechanical systems (MEMS), have converged to the extent that extremely small devices with diminutive power requirements are becoming more and more routine. These devices are ideally suited for carefully thought-out betavoltaic power solutions that can easily and safely offer nanoWatt-to-microWatt power levels with enduring 20-year lifetimes. ==Original Technology== Betacels utilized Pm-147 beta sources that were combined with custom designed silicon p-n junctions. Operational configurations involved stacking unidirectional-sources with Si p-n junctions in a series arrangement (Fig. 1). The power output of the Betacel was approximately 400 microWatts. The power density of the battery was approximately 0.025 milliWatts per cubic centimeter. The battery itself was approximately one cubic inch in volume (16 cm3). Most of the volume was used for shielding, as containment of the gamma radiation that was emitted from the Pm-146 contaminant within the Pm-147.〔"Betacel Nuclear Batteries for Biomedical Applications," L.C. Olsen and S.E Seeman, 8th Intersociety Energy Conversion Engineering Conference, Philadelphia, PA, page 451, August 13–17, 1973.〕 These Betacel batteries presented an efficiency of approximately 4%. However, higher efficiency devices were in the development process utilizing bidirectional beta sources. These bi-directional source devices would have yielded efficiencies approaching 8%. Unfortunately, these higher efficiency devices were never realized since pacemaker manufacturers focused on the use of Lithium batteries which did not utilize radioactive material, and could power pacemakers for 5 to 7 years. Although previous betavoltaic devices degraded rapidly due to radiation damage, the Betacel showed no deleterious effects from radiation. The power levels decreased as expected. In particular, the battery power decreased exponentially with a half-life of 2.62 years, the same as that for Pm-147. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Betacel」の詳細全文を読む スポンサード リンク
|